ZA200501677B - Hydantoin derivatives and their use as TACE inhibitors. - Google Patents
Hydantoin derivatives and their use as TACE inhibitors.Info
- Publication number
- ZA200501677B ZA200501677B ZA200501677A ZA200501677A ZA200501677B ZA 200501677 B ZA200501677 B ZA 200501677B ZA 200501677 A ZA200501677 A ZA 200501677A ZA 200501677 A ZA200501677 A ZA 200501677A ZA 200501677 B ZA200501677 B ZA 200501677B
- Authority
- ZA
- South Africa
- Prior art keywords
- hydantoin derivatives
- tace inhibitors
- tace
- inhibitors
- hydantoin
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/72—Two oxygen atoms, e.g. hydantoin
- C07D233/76—Two oxygen atoms, e.g. hydantoin with substituted hydrocarbon radicals attached to the third ring carbon atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Dermatology (AREA)
- Rheumatology (AREA)
- Pulmonology (AREA)
- Vascular Medicine (AREA)
- Pain & Pain Management (AREA)
- Urology & Nephrology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Transplantation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB0221246.2A GB0221246D0 (en) | 2002-09-13 | 2002-09-13 | Compounds |
Publications (1)
Publication Number | Publication Date |
---|---|
ZA200501677B true ZA200501677B (en) | 2005-09-12 |
Family
ID=9943999
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ZA200501677A ZA200501677B (en) | 2002-09-13 | 2005-02-25 | Hydantoin derivatives and their use as TACE inhibitors. |
Country Status (19)
Country | Link |
---|---|
US (2) | US20050256176A1 (is) |
EP (2) | EP1551826A1 (is) |
JP (2) | JP2006503829A (is) |
KR (1) | KR20050042499A (is) |
CN (1) | CN1681804A (is) |
AR (2) | AR041250A1 (is) |
AU (2) | AU2003263345A1 (is) |
BR (1) | BR0314275A (is) |
CA (1) | CA2497571A1 (is) |
GB (1) | GB0221246D0 (is) |
IS (1) | IS7792A (is) |
MX (1) | MXPA05002602A (is) |
NO (1) | NO20051788L (is) |
PL (1) | PL375877A1 (is) |
RU (1) | RU2005106353A (is) |
TW (2) | TW200406398A (is) |
UY (1) | UY27972A1 (is) |
WO (2) | WO2004024721A1 (is) |
ZA (1) | ZA200501677B (is) |
Families Citing this family (43)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SE0100902D0 (sv) | 2001-03-15 | 2001-03-15 | Astrazeneca Ab | Compounds |
SE0100903D0 (sv) * | 2001-03-15 | 2001-03-15 | Astrazeneca Ab | Compounds |
SE0103710D0 (sv) | 2001-11-07 | 2001-11-07 | Astrazeneca Ab | Compounds |
SE0202539D0 (sv) * | 2002-08-27 | 2002-08-27 | Astrazeneca Ab | Compounds |
GB0221246D0 (en) * | 2002-09-13 | 2002-10-23 | Astrazeneca Ab | Compounds |
US7132432B2 (en) * | 2003-06-05 | 2006-11-07 | Bristol-Myers Squibb Company | Hydantoin derivatives as inhibitors of tumor necrosis factor-alpha converting enzyme (TACE) |
WO2005000309A2 (en) * | 2003-06-27 | 2005-01-06 | Ionix Pharmaceuticals Limited | Chemical compounds |
GB0405101D0 (en) * | 2004-03-06 | 2004-04-07 | Astrazeneca Ab | Compounds |
BRPI0511642A (pt) | 2004-06-02 | 2008-01-02 | Lilly Co Eli | composto ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, métodos para inibir o receptor h3 da histamina em um mamìfero, para tratamento ou prevenção de um distúrbio do sistema nervoso ou outro distúrbio associado com o receptor h3 da histamina, para tratamento ou prevenção da obesidade, para tratamento ou prevenção de um distúrbio ou doença, e, uso de um composto ou um sal do mesmo |
US7648992B2 (en) | 2004-07-05 | 2010-01-19 | Astrazeneca Ab | Hydantoin derivatives for the treatment of obstructive airway diseases |
SE0401763D0 (sv) * | 2004-07-05 | 2004-07-05 | Astrazeneca Ab | Compounds |
SE0401762D0 (sv) * | 2004-07-05 | 2004-07-05 | Astrazeneca Ab | Novel compounds |
US7504424B2 (en) | 2004-07-16 | 2009-03-17 | Schering Corporation | Compounds for the treatment of inflammatory disorders |
US7482370B2 (en) * | 2004-07-16 | 2009-01-27 | Schering Corporation | Compounds for the treatment of inflammatory disorders |
US7488745B2 (en) | 2004-07-16 | 2009-02-10 | Schering Corporation | Compounds for the treatment of inflammatory disorders |
SE0403085D0 (sv) * | 2004-12-17 | 2004-12-17 | Astrazeneca Ab | Novel componds |
SE0403086D0 (sv) * | 2004-12-17 | 2004-12-17 | Astrazeneca Ab | Compounds |
AR059036A1 (es) | 2006-01-17 | 2008-03-12 | Schering Corp | Compuestos para el tratamiento de trastornos inflamatorios |
US7612212B2 (en) | 2006-02-22 | 2009-11-03 | Hoffmann-La Roche Inc. | Substituted hydantoins |
TW200740769A (en) | 2006-03-16 | 2007-11-01 | Astrazeneca Ab | Novel process |
DK2041181T3 (da) * | 2006-06-08 | 2011-08-29 | Helmholtz Zentrum Muenchen | Specifikke proteaseinhibitorer og deres anvendelse i cancerterapi |
BRPI0702900A2 (pt) * | 2006-06-28 | 2011-03-15 | Teva Pharma | formas cristalinas da atorvastatina |
TW200831488A (en) * | 2006-11-29 | 2008-08-01 | Astrazeneca Ab | Novel compounds |
US8188314B2 (en) * | 2008-06-24 | 2012-05-29 | Valeant Pharmaceuticals International | Benzyloxy anilide derivatives useful as potassium channel modulators |
WO2010036638A2 (en) | 2008-09-24 | 2010-04-01 | Schering Corporation | Compounds for the treatment of inflammatory disorders |
AR073741A1 (es) | 2008-09-24 | 2010-12-01 | Schering Corp | Derivados heterociclicos de hidantoina, composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento de enfermedades inflamatorias, tales como psoriasis o artritis |
WO2010054278A2 (en) | 2008-11-10 | 2010-05-14 | Schering Corporation | Compounds for the treatment of inflammatory disorders |
WO2010054279A1 (en) | 2008-11-10 | 2010-05-14 | Schering Corporation | Compounds for the treatment of inflammatory disorders |
EP2789607B1 (en) * | 2011-12-09 | 2018-02-07 | Kaken Pharmaceutical Co., Ltd. | Pyridone derivative and medicine containing same |
WO2014107622A1 (en) | 2013-01-07 | 2014-07-10 | University Of Southern California | Deoxyuridine triphosphatase inhibitors |
EP3006437B1 (en) | 2013-06-07 | 2020-08-05 | Kaken Pharmaceutical Co., Ltd. | (+)-5-(3,4-difluorophenyl)-5-[(3-methyl-2-oxopyridin-1(2h)-yl)methyl]imidazolidine-2,4-dione and drug containing same |
WO2017006271A1 (en) | 2015-07-08 | 2017-01-12 | University Of Southern California | Deoxyuridine triphosphatase inhibitors containing amino sulfonyl linkage |
US10577321B2 (en) | 2015-07-08 | 2020-03-03 | University Of Southern California | Deoxyuridine triphosphatase inhibitors |
EP3319939A1 (en) | 2015-07-08 | 2018-05-16 | CV6 Therapeutics (NI) Limited | Hydantoin containing deoxyuridine triphosphatase inhibitors |
US10544105B2 (en) | 2015-07-08 | 2020-01-28 | Cv6 Therapeutics (Ni) Limited | Deoxyuridine triphosphatase inhibitors containing cyclopropano linkage |
WO2018098207A1 (en) | 2016-11-23 | 2018-05-31 | Cv6 Therapeutics (Ni) Limited | Hydantoin containing deoxyuridine triphosphatase inhibitors |
US11168059B2 (en) | 2016-11-23 | 2021-11-09 | Cv6 Therapeutics (Ni) Limited | Amino sulfonyl compounds |
US11174271B2 (en) | 2016-11-23 | 2021-11-16 | Cv6 Therapeutics (Ni) Limited | 6-membered uracil isosteres |
US10829457B2 (en) | 2016-11-23 | 2020-11-10 | Cv6 Therapeutics (Ni) Limited | Nitrogen ring linked deoxyuridine triphosphatase inhibitors |
WO2018098206A1 (en) * | 2016-11-23 | 2018-05-31 | Cv6 Therapeutics (Ni) Limited | Hydantoin containing deoxyuridine triphosphatase inhibitors |
US11247984B2 (en) | 2017-01-05 | 2022-02-15 | Cv6 Therapeutics (Ni) Limited | Uracil containing compounds |
EP3822268A1 (en) | 2019-11-15 | 2021-05-19 | Bayer Aktiengesellschaft | Substituted hydantoinamides as adamts7 antagonists |
EP3822265A1 (en) | 2019-11-15 | 2021-05-19 | Bayer AG | Substituted hydantoinamides as adamts7 antagonists |
Family Cites Families (36)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2745875A (en) * | 1953-06-30 | 1956-05-15 | Hoechst Ag | Preparation of nu-acylamino-phenylpropane diols |
US3452040A (en) * | 1966-01-05 | 1969-06-24 | American Home Prod | 5,5-disubstituted hydantoins |
US3529019A (en) * | 1968-04-23 | 1970-09-15 | Colgate Palmolive Co | Alkylaryloxy alanines |
US3849574A (en) * | 1971-05-24 | 1974-11-19 | Colgate Palmolive Co | Alpha-substituted-beta-arylthioalkyl amino-acids,for increasing heart rate |
US4315031A (en) * | 1977-09-01 | 1982-02-09 | Science Union Et Cie | Thiosubstituted amino acids |
GB1601310A (en) * | 1978-05-23 | 1981-10-28 | Lilly Industries Ltd | Aryl hydantoins |
JPS61212292A (ja) * | 1985-03-19 | 1986-09-20 | Mitsui Toatsu Chem Inc | D−α−アミノ酸の製造方法 |
PH31245A (en) * | 1991-10-30 | 1998-06-18 | Janssen Pharmaceutica Nv | 1,3-Dihydro-2H-imidazoÄ4,5-BÜ-quinolin-2-one derivatives. |
US5308853A (en) * | 1991-12-20 | 1994-05-03 | Warner-Lambert Company | Substituted-5-methylidene hydantoins with AT1 receptor antagonist properties |
US5246943A (en) * | 1992-05-19 | 1993-09-21 | Warner-Lambert Company | Substituted 1,2,3,4-tetahydroisoquinolines with angiotensin II receptor antagonist properties |
US6166041A (en) * | 1995-10-11 | 2000-12-26 | Euro-Celtique, S.A. | 2-heteroaryl and 2-heterocyclic benzoxazoles as PDE IV inhibitors for the treatment of asthma |
ATE215946T1 (de) * | 1995-11-22 | 2002-04-15 | Darwin Discovery Ltd | Mercaptoalkylpeptidylverbindungen mit einem imidazolsubstituenten und ihre verwendung als inhibitoren der matrix metalloproteinasen (mmp) und/oder des tumor necrosis faktors (tnf) |
GB9616643D0 (en) * | 1996-08-08 | 1996-09-25 | Chiroscience Ltd | Compounds |
US5919790A (en) * | 1996-10-11 | 1999-07-06 | Warner-Lambert Company | Hydroxamate inhibitors of interleukin-1β converting enzyme |
ATE212619T1 (de) * | 1996-10-22 | 2002-02-15 | Upjohn Co | Alpha-amino sulfonyl hydroxamsäure als matrix metalloproteinase inhibitoren |
EP0983239A1 (en) * | 1997-05-06 | 2000-03-08 | Novo Nordisk A/S | Novel heterocyclic compounds |
EP0877019B1 (de) * | 1997-05-09 | 2001-12-12 | Hoechst Aktiengesellschaft | Substituierte Diaminocarbonsäuren |
HUP0101176A3 (en) * | 1998-02-04 | 2002-06-28 | Novartis Ag | Sulfonylamino derivatives which inhibit matrix-degrading metalloproteinases, process for their preparation and pharmaceutical compositions containing them |
US6329418B1 (en) * | 1998-04-14 | 2001-12-11 | The Procter & Gamble Company | Substituted pyrrolidine hydroxamate metalloprotease inhibitors |
JP2002514644A (ja) * | 1998-05-14 | 2002-05-21 | デュポン ファーマシューティカルズ カンパニー | メタロプロテイナーゼ阻害剤としての置換アリールヒドロキサム酸 |
JP2002518368A (ja) * | 1998-06-17 | 2002-06-25 | デュポン ファーマシューティカルズ カンパニー | メタロプロテイナーゼ阻害剤としての環式ヒドロキサム酸類 |
US6339101B1 (en) * | 1998-08-14 | 2002-01-15 | Gpi Nil Holdings, Inc. | N-linked sulfonamides of N-heterocyclic carboxylic acids or isosteres for vision and memory disorders |
US6114361A (en) * | 1998-11-05 | 2000-09-05 | Pfizer Inc. | 5-oxo-pyrrolidine-2-carboxylic acid hydroxamide derivatives |
US6340691B1 (en) * | 1999-01-27 | 2002-01-22 | American Cyanamid Company | Alkynyl containing hydroxamic acid compounds as matrix metalloproteinase and tace inhibitors |
ATE305782T1 (de) * | 1999-08-12 | 2005-10-15 | Pharmacia Italia Spa | 3(5)-amino-pyrazolderivate, deren herstellungsverfahren und verwendung als krebshemmende mittel |
US6525202B2 (en) * | 2000-07-17 | 2003-02-25 | Wyeth | Cyclic amine phenyl beta-3 adrenergic receptor agonists |
US20020091107A1 (en) * | 2000-09-08 | 2002-07-11 | Madar David J. | Oxazolidinone antibacterial agents |
DE10047073C1 (de) * | 2000-09-22 | 2002-01-24 | Dbt Gmbh | Hydraulisch schaltbares Wegeventil |
SE0100903D0 (sv) * | 2001-03-15 | 2001-03-15 | Astrazeneca Ab | Compounds |
SE0100902D0 (sv) * | 2001-03-15 | 2001-03-15 | Astrazeneca Ab | Compounds |
US20040147573A1 (en) * | 2001-03-15 | 2004-07-29 | Anders Eriksson | Metalloproteinase inhibitors |
ATE445400T1 (de) * | 2001-05-25 | 2009-10-15 | Bristol Myers Squibb Co | Hydantion-derivate als hemmer von matrix- metalloproteinasen |
SE0103710D0 (sv) * | 2001-11-07 | 2001-11-07 | Astrazeneca Ab | Compounds |
SE0202539D0 (sv) * | 2002-08-27 | 2002-08-27 | Astrazeneca Ab | Compounds |
GB0221246D0 (en) * | 2002-09-13 | 2002-10-23 | Astrazeneca Ab | Compounds |
TWI220073B (en) * | 2003-07-24 | 2004-08-01 | Au Optronics Corp | Method for manufacturing polysilicon film |
-
2002
- 2002-09-13 GB GBGB0221246.2A patent/GB0221246D0/en not_active Ceased
-
2003
- 2003-09-05 TW TW092124646A patent/TW200406398A/zh unknown
- 2003-09-05 TW TW092124627A patent/TW200409769A/zh unknown
- 2003-09-09 CN CNA038219557A patent/CN1681804A/zh active Pending
- 2003-09-09 WO PCT/GB2003/003914 patent/WO2004024721A1/en not_active Application Discontinuation
- 2003-09-09 AU AU2003263345A patent/AU2003263345A1/en not_active Abandoned
- 2003-09-09 AU AU2003263347A patent/AU2003263347A1/en not_active Abandoned
- 2003-09-09 CA CA002497571A patent/CA2497571A1/en not_active Abandoned
- 2003-09-09 BR BR0314275-2A patent/BR0314275A/pt not_active Application Discontinuation
- 2003-09-09 KR KR1020057004211A patent/KR20050042499A/ko not_active Application Discontinuation
- 2003-09-09 WO PCT/GB2003/003907 patent/WO2004024715A1/en not_active Application Discontinuation
- 2003-09-09 RU RU2005106353/04A patent/RU2005106353A/ru not_active Application Discontinuation
- 2003-09-09 EP EP03795075A patent/EP1551826A1/en not_active Withdrawn
- 2003-09-09 US US10/527,349 patent/US20050256176A1/en not_active Abandoned
- 2003-09-09 EP EP03795072A patent/EP1539740A1/en not_active Withdrawn
- 2003-09-09 US US10/527,215 patent/US20060063818A1/en not_active Abandoned
- 2003-09-09 MX MXPA05002602A patent/MXPA05002602A/es not_active Application Discontinuation
- 2003-09-09 PL PL03375877A patent/PL375877A1/xx not_active Application Discontinuation
- 2003-09-09 JP JP2004535650A patent/JP2006503829A/ja active Pending
- 2003-09-09 JP JP2004535653A patent/JP2006507248A/ja active Pending
- 2003-09-11 UY UY27972A patent/UY27972A1/es not_active Application Discontinuation
- 2003-09-12 AR ARP030103317A patent/AR041250A1/es unknown
- 2003-09-12 AR ARP030103319A patent/AR043049A1/es unknown
-
2005
- 2005-02-25 ZA ZA200501677A patent/ZA200501677B/xx unknown
- 2005-04-11 IS IS7792A patent/IS7792A/is unknown
- 2005-04-12 NO NO20051788A patent/NO20051788L/no unknown
Also Published As
Publication number | Publication date |
---|---|
MXPA05002602A (es) | 2005-05-05 |
AU2003263347A1 (en) | 2004-04-30 |
IS7792A (is) | 2005-04-11 |
AR041250A1 (es) | 2005-05-11 |
TW200409769A (en) | 2004-06-16 |
US20060063818A1 (en) | 2006-03-23 |
WO2004024721A1 (en) | 2004-03-25 |
RU2005106353A (ru) | 2005-10-10 |
AR043049A1 (es) | 2005-07-13 |
JP2006503829A (ja) | 2006-02-02 |
EP1539740A1 (en) | 2005-06-15 |
WO2004024715A1 (en) | 2004-03-25 |
US20050256176A1 (en) | 2005-11-17 |
CN1681804A (zh) | 2005-10-12 |
EP1551826A1 (en) | 2005-07-13 |
UY27972A1 (es) | 2004-04-30 |
CA2497571A1 (en) | 2004-03-25 |
GB0221246D0 (en) | 2002-10-23 |
BR0314275A (pt) | 2005-08-09 |
NO20051788L (no) | 2005-06-13 |
JP2006507248A (ja) | 2006-03-02 |
PL375877A1 (en) | 2005-12-12 |
AU2003263345A1 (en) | 2004-04-30 |
TW200406398A (en) | 2004-05-01 |
KR20050042499A (ko) | 2005-05-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ZA200501677B (en) | Hydantoin derivatives and their use as TACE inhibitors. | |
AP2003002857A0 (en) | New spirotricyclic derivatives and their use as phosphodiesterase-7 inhibitors. | |
EG25482A (en) | Inhibitors | |
AU2003202263A1 (en) | Roh-kinase inhibitors | |
AU2003259749A1 (en) | 3-pyrrolyl-pyridopyrazoles and 3-pyrrolyl-indazoles as novel kinase inhibitors | |
HK1071360A1 (en) | 2-hydroxy-3-heteroarylindole derivatives as gsk3 inhibitors | |
AU2003249442A1 (en) | Kinase inhibitors | |
AU2003222055A1 (en) | Kinase inhibitors | |
IL165515A0 (en) | Bisindolyl-maleimid derivatives as kinase inhibitors | |
AU2003216660A1 (en) | N-substituted-heteroaryloxy-aryl-spiro-pyrimidine-2,4,6-trione metalloproteinase inhibitors | |
HK1091492A1 (en) | Hydantoin derivatives as mmp inhibitors | |
PL376129A1 (en) | Pyridazinone derivatives as gsk-3beta inhibitors | |
NO20053356D0 (no) | Aminindazolderivater og anvendelse derav som kinaseinhibitorer. | |
AU2003271566A1 (en) | Pyrrolopyrazines as kinase inhibitors | |
AU2003219410A1 (en) | Triaryl-oxy-aryl-spiro-pyrimidine-2, 4, 6-trione metalloproteinase inhibitors | |
AU2002228317A1 (en) | Benz-1,3-azole derivatives and their uses as heparanase inhibitors | |
AU2003232848A1 (en) | Phenylaminopyrimidines and their use as rho-kinase inhibitors | |
AU2003249683A1 (en) | Nf-:b inhibitors | |
AU2003220437A1 (en) | Thiopyrimidine and isothiazolopyrimidine kinase inhibitors | |
AU2003216677A1 (en) | Triaryl-oxy-aryloxy-pyrimidine-2,4,6-trione metalloproteinase inhibitors | |
PL374581A1 (en) | Diaminothiazoles and use thereof as cdk4 inhibitors | |
AU2003230392A1 (en) | Beta-secretase inhibitors | |
AU2003302588A1 (en) | Phosphodiesterase 10a inhibitors | |
AU2003258942A1 (en) | Imidazolidinedione-derivatives and their use as metalloproteinase inhibitors | |
AU2003292720A8 (en) | Dihydrothienoquinoline derivatives and cell adhesion inhibitors containing the same |